Lipocine (NASDAQ:LPCN) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Lipocine (NASDAQ:LPCN) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Weiss Ratings lowered shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $15.00.

Lipocine Price Performance

Shares of LPCN stock opened at $2.23 on Friday. The business has a fifty day moving average of $2.31 and a 200 day moving average of $5.33. Lipocine has a 1 year low of $1.81 and a 1 year high of $12.37. The firm has a market capitalization of $18.38 million, a price-to-earnings ratio of -1.19 and a beta of 0.44.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The firm had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.16 million. Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. As a group, equities research analysts expect that Lipocine will post -1.91 earnings per share for the current year.

Hedge Funds Weigh In On Lipocine

A number of institutional investors have recently modified their holdings of LPCN. Seven Fleet Capital Management LP acquired a new position in shares of Lipocine in the 1st quarter valued at about $998,000. Stempoint Capital LP acquired a new stake in Lipocine during the first quarter worth about $1,282,000. ADAR1 Capital Management LLC purchased a new position in Lipocine during the first quarter valued at approximately $185,000. Eversept Partners LP acquired a new position in Lipocine in the first quarter valued at approximately $2,357,000. Finally, Exome Asset Management LLC acquired a new position in Lipocine in the first quarter valued at approximately $486,000. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.